文献速递角膜与眼表疾病眼整形与眼眶

间充质干细胞外泌体在Stevens-Johnson综合征小鼠模型中的给药途径依赖性疗效与组织滞留

Route-Dependent Therapeutic Effects and Tissue Retention of Mesenchymal Stem Cell-Derived Exosomes in a Murine Model of Stevens-Johnson Syndrome.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究在IKZF转基因小鼠Stevens-Johnson综合征(SJS)合并过敏性眼病(AED)模型中,评估间充质干细胞外泌体(MSC-exos)对眼表炎症的治疗潜力及免疫反应特征。结果显示MSC-exos显著降低临床疾病严重度,结膜下给药改善最显著且与皮质激素治疗相当;药代动力学成像显示结膜下给药可在眼组织滞留长达72小时,而局部滴用迅速清除。

要点

  • MSC-exos显著减轻IKZF+AED小鼠眼表炎症,结膜下给药疗效最佳且与皮质激素相当。
  • 结膜下给药使外泌体在眼组织滞留达72小时并定位于结膜基质,局部滴用则快速清除。
  • IKZF+AED模型显示结膜局部炎症及引流淋巴结CD4⁺T细胞活化,符合SJS相关眼病特征。

核心结论

  • MSC-exos可显著改善IKZF+AED小鼠的临床炎症,其疗效受给药途径强烈影响。
  • 结膜下给药后外泌体在结膜组织内长时间滞留,提示结膜组织内药代动力学暴露可能是疗效的关键决定因素。

研究设计与样本

  • 使用表达IKZF1的转基因小鼠作为SJS模型,通过腹腔注射卵清蛋白/氢氧化铝/百日咳毒素免疫并局部卵清蛋白激发诱导眼表炎症。
  • 用流式细胞术分析结膜组织和引流淋巴结的免疫反应。
  • MSC-exos来自永生化人胚胎干细胞来源的间充质干细胞,每日评估临床疾病。
  • 使用Alexa Fluor 488标记的MSC-exos通过活体多光子共聚焦显微镜追踪药代动力学。

主要发现

  • IKZF小鼠结膜免疫细胞浸润较野生型对照增加,过敏激发后进一步放大。
  • IKZF+AED小鼠结膜固有和适应性免疫细胞群体扩增,引流淋巴结中产生细胞因子的CD4⁺T细胞频率增加。
  • MSC-exo治疗显著降低临床疾病严重度,结膜下给药改善最大,与皮质激素治疗相当。
  • 药代动力学成像显示局部滴用外泌体迅速清除,结膜下给药则滞留于眼组织长达72小时并定位于结膜基质。

临床怎么用

  • 在SJS相关眼表炎症中,MSC-exos结膜下给药可能比局部滴用提供更持久的治疗暴露。
  • 结膜下给药疗效与皮质激素治疗相当,提示MSC-exos可能作为激素替代或辅助治疗的潜在选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To test the therapeutic potential of mesenchymal stem cell-derived exosomes (MSC-exos) in ocular surface inflammation and to characterize immune responses in an IKAROS family zinc finger (IKZF) murine model of Stevens-Johnson syndrome (SJS) with allergic eye disease (AED). METHODS: Transgenic mice expressing IKZF1 were used as the SJS model. To induce ocular surface inflammation, the mice were immunized with intraperitoneal ovalbumin in aluminum hydroxide (alum) and pertussis toxin and challenged with topical ovalbumin. Conjunctival tissues and draining lymph nodes (LNs) were analyzed by flow cytometry to characterize immune responses. MSC-exos were prepared from immortalized human embryonic stem cell-derived MSCs. Clinical disease was evaluated daily. The pharmacokinetics of Alexa Fluor 488-labeled MSC-exos were tracked using in vivo multiphoton confocal microscopy. RESULTS: IKZF mice demonstrated increased conjunctival immune cell infiltration compared with wild-type controls, which was further amplified following allergic challenge. IKZF+AED mice exhibited expansion of innate and adaptive populations in the conjunctiva. Draining LNs showed increased frequencies of cytokine-producing CD4⁺ T cells. MSC-exo treatment significantly reduced clinical disease severity, with subconjunctival administration producing the greatest improvement, comparable to corticosteroid therapy. Pharmacokinetic imaging demonstrated rapid clearance of topically administered exosomes, whereas subconjunctival delivery resulted in retention within ocular tissues for up to 72 hours and localization within the conjunctival stroma. CONCLUSIONS: The IKZF+AED model demonstrates local conjunctival inflammation and systemic T-cell activation consistent with SJS-associated ocular disease. MSC-exos significantly improved clinical inflammation, and their therapeutic efficacy was strongly influenced by delivery route. Prolonged tissue retention following subconjunctival administration suggests that pharmacokinetic exposure within conjunctival tissues may be a key determinant of therapeutic effect.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Khodor A, Ma S, Komai S, et al. Route-Dependent Therapeutic Effects and Tissue Retention of Mesenchymal Stem Cell-Derived Exosomes in a Murine Model of Stevens-Johnson Syndrome. Invest Ophthalmol Vis Sci. 2026. PMID: 42479023. doi:10.1167/iovs.67.8.44

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。